» Articles » PMID: 27815375

Estimating Longitudinal Risks and Benefits From Cardiovascular Preventive Therapies Among Medicare Patients: The Million Hearts Longitudinal ASCVD Risk Assessment Tool: A Special Report From the American Heart Association and American College Of...

Overview
Journal Circulation
Date 2016 Nov 6
PMID 27815375
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

The Million Hearts Initiative has a goal of preventing 1 million heart attacks and strokes-the leading causes of mortality-through several public health and healthcare strategies by 2017. The American Heart Association and American College of Cardiology support the program. The Cardiovascular Risk Reduction Model was developed by Million Hearts and the Center for Medicare & Medicaid Services as a strategy to assess a value-based payment approach toward reduction in 10-year predicted risk of atherosclerotic cardiovascular disease (ASCVD) by implementing cardiovascular preventive strategies to manage the "ABCS" (aspirin therapy in appropriate patients, blood pressure control, cholesterol management, and smoking cessation). The purpose of this special report is to describe the development and intended use of the Million Hearts Longitudinal ASCVD Risk Assessment Tool. The Million Hearts Tool reinforces and builds on the "2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk" by allowing clinicians to estimate baseline and updated 10-year ASCVD risk estimates for primary prevention patients adhering to the appropriate ABCS over time, alone or in combination. The tool provides updated risk estimates based on evidence from high-quality systematic reviews and meta-analyses of the ABCS therapies. This novel approach to personalized estimation of benefits from risk-reducing therapies in primary prevention may help target therapies to those in whom they will provide the greatest benefit, and serves as the basis for a Center for Medicare & Medicaid Services program designed to evaluate the Million Hearts Cardiovascular Risk Reduction Model.

Citing Articles

Smoking Cessation and Incident Cardiovascular Disease.

Cho J, Shin S, Kim H, Kim M, Byeon K, Jung M JAMA Netw Open. 2024; 7(11):e2442639.

PMID: 39485349 PMC: 11530932. DOI: 10.1001/jamanetworkopen.2024.42639.


Evaluating a multicomponent intervention for managing kidney outcomes among patients with moderate or advanced chronic kidney disease (CKD): protocol for the Strategies for Kidney Outcomes Prevention and Evaluation (SKOPE) randomized controlled trial.

Jafar T, Tan N, Gandhi M, Yoon S, Finkelstein E, Seng P Trials. 2024; 25(1):730.

PMID: 39472975 PMC: 11523586. DOI: 10.1186/s13063-024-08564-1.


Sex Differences in the Relationship Between Self-Reporting of Snoring and Cardiovascular Risk:An Analysis of NHANES.

Wang J, Ye Y, Chen X, Hu X, Peng Y Nat Sci Sleep. 2024; 16:965-977.

PMID: 39050367 PMC: 11268715. DOI: 10.2147/NSS.S467516.


Predicting cardiovascular disease risk using photoplethysmography and deep learning.

Weng W, Baur S, Daswani M, Chen C, Harrell L, Kakarmath S PLOS Glob Public Health. 2024; 4(6):e0003204.

PMID: 38833495 PMC: 11149850. DOI: 10.1371/journal.pgph.0003204.


Global Prevalence of Aspirin Use for Primary Prevention of Cardiovascular Disease: A Cross-Sectional Study of Nationally Representative, Individual-Level Data.

Yoo S, Chung G, Bahendeka S, Sibai A, Damasceno A, Farzadfar F Glob Heart. 2024; 19(1):44.

PMID: 38708405 PMC: 11067965. DOI: 10.5334/gh.1323.


References
1.
. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143-421. View

2.
Ettehad D, Emdin C, Kiran A, Anderson S, Callender T, Emberson J . Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016; 387(10022):957-967. DOI: 10.1016/S0140-6736(15)01225-8. View

3.
Grundy S, Cleeman J, Merz C, Brewer Jr H, Clark L, Hunninghake D . Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110(2):227-39. DOI: 10.1161/01.CIR.0000133317.49796.0E. View

4.
Lloyd-Jones D, Leip E, Larson M, DAgostino R, Beiser A, Wilson P . Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006; 113(6):791-8. DOI: 10.1161/CIRCULATIONAHA.105.548206. View

5.
Lloyd-Jones D, Hong Y, Labarthe D, Mozaffarian D, Appel L, Van Horn L . Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. Circulation. 2010; 121(4):586-613. DOI: 10.1161/CIRCULATIONAHA.109.192703. View